UCD School of Veterinary Medicine and UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland; AnaBio Technologies Ltd, IDA Business Park, Carrigtwohill, Co. Cork, Ireland.
School of Pharmacy, Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin 2, Ireland.
J Pharm Sci. 2018 Jun;107(6):1648-1655. doi: 10.1016/j.xphs.2018.02.012. Epub 2018 Feb 17.
In addition to their solubilizing properties, excipients used in lipid-based formulations can improve intestinal permeability of macromolecules. We determined whether admixing of medium-chain fatty acid (MCFA) permeation enhancers with a lipoidal excipient (Labrasol) could potentiate transepithelial flux of a poorly permeable macromolecule (fluorescein isothiocyanate dextran 4 kDa [FD4]) across rat intestinal mucosae mounted in Ussing chambers. Low concentrations of sodium caprate (C), sodium undecylenate (C), or sodium laurate (C) combined with Labrasol increased the apparent permeability coefficient (P) of FD4 to values typically seen with higher concentrations of MCFAs or Labrasol alone. For example, combination of C (0.5 mg/mL) with Labrasol (1 mg/mL) increased the P of FD4 by 10- and 11-fold over the respective individual agents at the same concentrations where no enhancement was evident. The increased enhancement ratios seen with the combinations were associated with some perturbation in intestinal histology and with attenuation of an epithelial functional measure, carbachol-stimulated inward short-circuit current. In conclusion, combining three MCFAs separately with Labrasol increased the P of FD4 to values greater than those seen for MCFAs or Labrasol alone. Ultimately, this may permit lower concentrations of MCFA to be used in combination with other excipients in oral formulations of poorly permeable molecules.
除了增溶作用外,脂质体制剂中的赋形剂还可以改善大分子的肠道通透性。我们研究了将中链脂肪酸(MCFA)渗透增强剂与脂质赋形剂(Labrasol)混合是否可以增强荧光素异硫氰酸酯葡聚糖 4kDa(FD4)等通透性差的大分子穿过 Ussing 室中肠黏膜的跨上皮通量。低浓度的癸酸钠(C)、十一烯酸钠(C)或月桂酸钠(C)与 Labrasol 联合使用可将 FD4 的表观渗透系数(P)增加至与单独使用更高浓度的 MCFAs 或 Labrasol 时相似的值。例如,将 C(0.5mg/mL)与 Labrasol(1mg/mL)组合使用时,在相同浓度下,FD4 的 P 分别增加了 10 倍和 11 倍,而在没有增强作用的情况下,P 没有增加。与单独使用各试剂相比,组合使用时增强比增加与肠组织学的某些改变以及上皮功能测量(乙酰胆碱刺激的内向短路电流)的衰减有关。总之,将三种 MCFAs 分别与 Labrasol 组合使用可将 FD4 的 P 增加到高于 MCFAs 或 Labrasol 单独使用的值。最终,这可能允许在口服渗透性差的分子制剂中以较低浓度的 MCFA 与其他赋形剂联合使用。